Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Muscle atrophy results from GM2 Gangliosidosis, also referred to as Tay-Sachs disease, which is brought on by a mutation in the HEXA genes. Treatment for this disease is typically symptom-specific because there is currently no known cure. Signs and symptoms include mucus accumulation in the lungs, seizures, loss of movement, vision, and hearing, as well as exaggerated reactions to loud noises. Tay-Sachs disease is also known as hexosaminidase disease. A deficiency is an uncommon hereditary neurological disorder resulting from insufficient hexosaminidase A, an enzyme that builds up G2 gangliosides. These substances accumulate in the brain, altering the activity of nerve cells and leading to additional neurological problems.